ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab |
|
|
| Active, not recruiting | 3 | 120 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 01/24 | 12/24 | | |
HOPE-3, NCT05126758: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy |
|
|
| Recruiting | 3 | 102 | US | CAP-1002, Cardiosphere-Derived Cells (CDCs), Placebo | Capricor Inc. | Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases | 12/24 | 12/26 | | |
